Lai L, Chen X, Tian G, Liang R, Chen X, Qin Y
Cancer Control. 2022; 29:10732748221106268.
PMID: 35844176
PMC: 9290152.
DOI: 10.1177/10732748221106268.
Sugasti-Salazar M, Campos D, Valdes-Torres P, Galan-Jurado P, Gonzalez-Santamaria J
Viruses. 2022; 14(2).
PMID: 35216015
PMC: 8878588.
DOI: 10.3390/v14020422.
Bellon M, Nicot C
J Virol. 2021; 96(3):e0196021.
PMID: 34818069
PMC: 8826812.
DOI: 10.1128/JVI.01960-21.
Abo-Al-Ela H
Mol Genet Genomics. 2021; 296(4):765-781.
PMID: 33904988
DOI: 10.1007/s00438-021-01786-x.
Cervantes-Gomez F, Stellrecht C, Ayres M, Keating M, Wierda W, Gandhi V
Oncotarget. 2019; 10(29):2793-2809.
PMID: 31073371
PMC: 6497463.
DOI: 10.18632/oncotarget.26876.
The regulatory role of protein phosphorylation in human gammaherpesvirus associated cancers.
Wang Y, Banerjee S, Ding L, Cai C, Wei F, Cai Q
Virol Sin. 2017; 32(5):357-368.
PMID: 29116588
PMC: 6704201.
DOI: 10.1007/s12250-017-4081-9.
Phosphorylation of Notch1 by Pim kinases promotes oncogenic signaling in breast and prostate cancer cells.
Santio N, Landor S, Vahtera L, Yla-Pelto J, Paloniemi E, Imanishi S
Oncotarget. 2016; 7(28):43220-43238.
PMID: 27281612
PMC: 5190019.
DOI: 10.18632/oncotarget.9215.
PIM kinase (and Akt) biology and signaling in tumors.
Warfel N, Kraft A
Pharmacol Ther. 2015; 151:41-9.
PMID: 25749412
PMC: 4957637.
DOI: 10.1016/j.pharmthera.2015.03.001.
EBNA3C augments Pim-1 mediated phosphorylation and degradation of p21 to promote B-cell proliferation.
Banerjee S, Lu J, Cai Q, Sun Z, Jha H, Robertson E
PLoS Pathog. 2014; 10(8):e1004304.
PMID: 25121590
PMC: 4133388.
DOI: 10.1371/journal.ppat.1004304.
Tricyclic Benzo[cd]azulenes selectively inhibit activities of Pim kinases and restrict growth of Epstein-Barr virus-transformed cells.
Kiriazis A, Vahakoski R, Santio N, Arnaudova R, Eerola S, Rainio E
PLoS One. 2013; 8(2):e55409.
PMID: 23405147
PMC: 3566155.
DOI: 10.1371/journal.pone.0055409.
PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
Brault L, Menter T, Obermann E, Knapp S, Thommen S, Schwaller J
Br J Cancer. 2012; 107(3):491-500.
PMID: 22722314
PMC: 3405213.
DOI: 10.1038/bjc.2012.272.
Genome-wide siRNA screen for mediators of NF-κB activation.
Gewurz B, Towfic F, Mar J, Shinners N, Takasaki K, Zhao B
Proc Natl Acad Sci U S A. 2012; 109(7):2467-72.
PMID: 22308454
PMC: 3289371.
DOI: 10.1073/pnas.1120542109.
Proviral integration site 2 is required for interleukin-6 expression induced by interleukin-1, tumour necrosis factor-α and lipopolysaccharide.
Yang J, Li X, Hanidu A, Htut T, Sellati R, Wang L
Immunology. 2010; 131(2):174-82.
PMID: 20465571
PMC: 2967263.
DOI: 10.1111/j.1365-2567.2010.03286.x.
PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.
Brault L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J
Haematologica. 2010; 95(6):1004-15.
PMID: 20145274
PMC: 2878801.
DOI: 10.3324/haematol.2009.017079.
KSHV reactivation from latency requires Pim-1 and Pim-3 kinases to inactivate the latency-associated nuclear antigen LANA.
Cheng F, Weidner-Glunde M, Varjosalo M, Rainio E, Lehtonen A, Schulz T
PLoS Pathog. 2009; 5(3):e1000324.
PMID: 19266083
PMC: 2648312.
DOI: 10.1371/journal.ppat.1000324.
Pim-1 kinase phosphorylates RUNX family transcription factors and enhances their activity.
Aho T, Sandholm J, Peltola K, Ito Y, Koskinen P
BMC Cell Biol. 2006; 7:21.
PMID: 16684349
PMC: 1473194.
DOI: 10.1186/1471-2121-7-21.